Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer

This is an open-label phase I/II study evaluating the addition of ebastine to docetaxel in the treatment for metastatic castration resistant prostate cancer. Patients will be randomized in a 2:1 fashion to receive ebastine daily during and after treatment with a maximum of 10 courses of docetaxel. The primary endpoint is change in the profile of urinary and blood lipids to indicate absorption and possible efficacy of ebastine. Secondary endpoints include PSA response and radiologic progression free survival.

Trial Details

NCT ID
NCT06480110
Phase
PHASE1 / PHASE2
Sponsor
Copenhagen University Hospital, Rigshospitalet
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Docetaxel + Ebastine
  • Docetaxel
Locations (sample)
  • Copenhagen, Denmark|55.67594,12.56553

Key Eligibility Criteria

  • 1\. Have a histologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate (carcinomas with pure small-cell histology or…
  • 2\. Surgically or medically castrated, with serum testosterone levels of ≤ 50 ng/dL equivalent to 1.7 nmol/L. For patients, currently being treated…
  • 3\. Have evidence of disease progression after prior therapy for mCRPC:
  • Disease progression after initiation of most recent therapy is based on any of the following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →